Yoni Bock Email

VP R&D, Reagents and Consumables . Vizgen

Current Roles

Employees:
194
Revenue:
$29.9M
About
Vizgen is the life sciences company developing the next generation of Spatially Resolved Transcriptomics. The Company's proprietary MERFISH (multiplexed error-robust fluorescence in situ hybridization) technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology enables a wide range of tissue-scale basic research and translational medicine and is instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. MERFISH is used as a tool for several Human Cell Atlas projects and was named a “Technology to Watch in 2018” by Nature. Tools employing MERFISH help to advance data-driven drug discovery and development and enable new insights for clinical pathology and diagnostics. “Vizgen's MERFISH technology undoubtedly will emerge as the next-gen platform for high-resolution spatial biology,” said Dr. David R. Walt, Co-founder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School; Professor of Pathology, Brigham and Women's Hospital; Core Faculty, Wyss Institute for Bioinspired Engineering, Harvard University; HHMI Professor. “It enables comprehensive transcriptomics combined with proteomics and has both whole tissue and subcellular resolution. It checks all the boxes.”
Vizgen Address
61 Moulton Street
Cambridge, MA
United States
Vizgen Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.